Merck, Dynavax announce positive Heplisav results

Drug/CompanyIndicationResultsScoop
Phase II
Schering-Plough
Boceprevir
hepatitis C

After 48 weeks of therapy, three out of every four patients receiving boceprevir in combination with standard therapy had undetectable levels of the virus. That compares to 38 percent with undetectable viral levels in the standard therapy arm.

Schering-Plough data pushed down the share value of rival Vertex Pharmaceuticals.

Phase III
Dynavax and Merck
Heplisav
Hepatitis B

In the study, 95.1 percent of subjects who received Heplisav developed protective antibodies to hepatitis B versus 81.1 percent of subjects who received Engerix-B, a marketed drug.

Back in April the FDA put a clinical hold on the drug's development because one subject was suspected to have Wegener's granulomatosis, an rare inflammation of blood vessels. The hold is still in effect.

Merck, Dynavax announce positive Heplisav results

Suggested Articles

The CTAD presentation cleared up some questions about the dataset without delivering a telling blow for either side of the debate.

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.